EPIDEMIOLOGICAL AND CLINICAL FACTORS ASSOCIATED WITH COVID-19 REINFECTION IN PATIENTS TREATED IN A HIGH-ALTITUDE
W Gomez-Gonzales1, J Martínez2, L Chihuantito-Abal2
11School of Human Medicine-Ica Branch, San Juan Bautista Private University, Ica; 2Collective and Integral Health Research Group (SCI), Vice-Rectorate for Research, Andean University of Cusco; 3Research Group Prevention and Control of Infectious and Non-Infectious Diseases; Professional School of Human Medicine, San Juan Bautista Private University, Ica, Peru.
Background:
The COVID-19 pandemic has underscored the challenge of SARS-CoV-2 reinfection, particularly with the emergence of new variants. This study aimed to identify epidemiological and clinical factors associated with COVID-19 reinfection in patients treated in the Cusco Region of Peru during 2022, a high-altitude area with unique demographic and geographic characteristics.
Methods:
A retrospective, observational, case-control study was conducted, analyzing 216 patients (108 reinfection cases and 108 primary infection controls). Data were collected from clinical records and analyzed using statistical methods, including chi-square tests and multivariate regression. The study focused on demographic, epidemiological, and clinical factors, with statistical significance set at p<0.05.
Results:
Males had a 1.51 times higher risk of reinfection compared to females (p<0.05). Patients from regions outside Cusco had a 16.03 times higher risk of reinfection than local residents (p<0.05). No significant associations were found between reinfection and clinical factors such as symptoms or comorbidities. The overall reinfection rate was 0.97%, consistent with global trends.
Conclusion:
The findings suggest that high altitude may confer protective effects against reinfection, potentially due to physiological adaptations to hypoxia. Males and individuals with interregional mobility were identified as high-risk groups. These results highlight the need for tailored public health strategies in high-altitude regions, focusing on surveillance and prevention for vulnerable populations. Further research is recommended to explore the biological mechanisms underlying these findings and to assess the impact of emerging viral variants on reinfection dynamics.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:


